Cargando…
Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway
BACKGROUND: Acute myeloid leukemia (AML) is initiated and maintained by a subset of self-renewing leukemia stem cells (LSCs), which contribute to the progression, recurrence and therapeutic resistance of leukemia. However, the mechanisms underlying the maintenance of LSCs drug resistance have not be...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4357193/ https://www.ncbi.nlm.nih.gov/pubmed/25890196 http://dx.doi.org/10.1186/s12943-015-0326-0 |
_version_ | 1782361112274010112 |
---|---|
author | Zhang, Yi Chen, Hai-xuan Zhou, Shu-yan Wang, Shao-xiang Zheng, Kai Xu, Dan-dan Liu, Yu-ting Wang, Xiao-yan Wang, Xiao Yan, Hai-zhao Zhang, Li Liu, Qiu-ying Chen, Wan-qun Wang, Yi-fei |
author_facet | Zhang, Yi Chen, Hai-xuan Zhou, Shu-yan Wang, Shao-xiang Zheng, Kai Xu, Dan-dan Liu, Yu-ting Wang, Xiao-yan Wang, Xiao Yan, Hai-zhao Zhang, Li Liu, Qiu-ying Chen, Wan-qun Wang, Yi-fei |
author_sort | Zhang, Yi |
collection | PubMed |
description | BACKGROUND: Acute myeloid leukemia (AML) is initiated and maintained by a subset of self-renewing leukemia stem cells (LSCs), which contribute to the progression, recurrence and therapeutic resistance of leukemia. However, the mechanisms underlying the maintenance of LSCs drug resistance have not been fully defined. In this study, we attempted to elucidate the mechanisms of LSCs drug resistance. METHODS: We performed reverse phase protein arrays to analyze the expression of anti-apoptotic proteins in the LSC-enriched leukemia cell line KG-1a. Immuno-blotting, cell viability and clinical AML samples were evaluated to verify the micro-assay results. The characteristics and transcriptional regulation of survivin were analyzed with the relative luciferase reporter assay, mutant constructs, chromatin immuno-precipitation (ChIP), quantitative real-time reverse transcription polymerase chain reaction (RT-qPCR), and western blotting. The levels of Sp1, c-Myc, phospho-extracellular signal-regulated kinase (p-ERK), phospho-mitogen and stress-activated protein kinase (p-MSK) were investigated in paired CD34+ and CD34- AML patient samples. RESULTS: Survivin was highly over-expressed in CD34 + CD38- KG-1a cells and paired CD34+ AML patients compared with their differentiated counterparts. Functionally, survivin contributes to the drug resistance of LSCs, and Sp1 and c-Myc concurrently regulate levels of survivin transcription. Clinically, Sp1 and c-Myc were significantly up-regulated and positively correlated with survivin in CD34+ AML patients. Moreover, Sp1 and c-Myc were further activated by the ERK/MSK mitogen-activated protein kinase (MAPK) signaling pathway, modulating survivin levels. CONCLUSION: Our findings demonstrated that ERK/MSK/Sp1/c-Myc axis functioned as a critical regulator of survivin expression in LSCs, offering a potential new therapeutic strategy for LSCs therapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12943-015-0326-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4357193 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-43571932015-03-13 Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway Zhang, Yi Chen, Hai-xuan Zhou, Shu-yan Wang, Shao-xiang Zheng, Kai Xu, Dan-dan Liu, Yu-ting Wang, Xiao-yan Wang, Xiao Yan, Hai-zhao Zhang, Li Liu, Qiu-ying Chen, Wan-qun Wang, Yi-fei Mol Cancer Research BACKGROUND: Acute myeloid leukemia (AML) is initiated and maintained by a subset of self-renewing leukemia stem cells (LSCs), which contribute to the progression, recurrence and therapeutic resistance of leukemia. However, the mechanisms underlying the maintenance of LSCs drug resistance have not been fully defined. In this study, we attempted to elucidate the mechanisms of LSCs drug resistance. METHODS: We performed reverse phase protein arrays to analyze the expression of anti-apoptotic proteins in the LSC-enriched leukemia cell line KG-1a. Immuno-blotting, cell viability and clinical AML samples were evaluated to verify the micro-assay results. The characteristics and transcriptional regulation of survivin were analyzed with the relative luciferase reporter assay, mutant constructs, chromatin immuno-precipitation (ChIP), quantitative real-time reverse transcription polymerase chain reaction (RT-qPCR), and western blotting. The levels of Sp1, c-Myc, phospho-extracellular signal-regulated kinase (p-ERK), phospho-mitogen and stress-activated protein kinase (p-MSK) were investigated in paired CD34+ and CD34- AML patient samples. RESULTS: Survivin was highly over-expressed in CD34 + CD38- KG-1a cells and paired CD34+ AML patients compared with their differentiated counterparts. Functionally, survivin contributes to the drug resistance of LSCs, and Sp1 and c-Myc concurrently regulate levels of survivin transcription. Clinically, Sp1 and c-Myc were significantly up-regulated and positively correlated with survivin in CD34+ AML patients. Moreover, Sp1 and c-Myc were further activated by the ERK/MSK mitogen-activated protein kinase (MAPK) signaling pathway, modulating survivin levels. CONCLUSION: Our findings demonstrated that ERK/MSK/Sp1/c-Myc axis functioned as a critical regulator of survivin expression in LSCs, offering a potential new therapeutic strategy for LSCs therapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12943-015-0326-0) contains supplementary material, which is available to authorized users. BioMed Central 2015-03-07 /pmc/articles/PMC4357193/ /pubmed/25890196 http://dx.doi.org/10.1186/s12943-015-0326-0 Text en © Zhang et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Zhang, Yi Chen, Hai-xuan Zhou, Shu-yan Wang, Shao-xiang Zheng, Kai Xu, Dan-dan Liu, Yu-ting Wang, Xiao-yan Wang, Xiao Yan, Hai-zhao Zhang, Li Liu, Qiu-ying Chen, Wan-qun Wang, Yi-fei Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway |
title | Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway |
title_full | Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway |
title_fullStr | Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway |
title_full_unstemmed | Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway |
title_short | Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway |
title_sort | sp1 and c-myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the erk-msk mapk signaling pathway |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4357193/ https://www.ncbi.nlm.nih.gov/pubmed/25890196 http://dx.doi.org/10.1186/s12943-015-0326-0 |
work_keys_str_mv | AT zhangyi sp1andcmycmodulatedrugresistanceofleukemiastemcellsbyregulatingsurvivinexpressionthroughtheerkmskmapksignalingpathway AT chenhaixuan sp1andcmycmodulatedrugresistanceofleukemiastemcellsbyregulatingsurvivinexpressionthroughtheerkmskmapksignalingpathway AT zhoushuyan sp1andcmycmodulatedrugresistanceofleukemiastemcellsbyregulatingsurvivinexpressionthroughtheerkmskmapksignalingpathway AT wangshaoxiang sp1andcmycmodulatedrugresistanceofleukemiastemcellsbyregulatingsurvivinexpressionthroughtheerkmskmapksignalingpathway AT zhengkai sp1andcmycmodulatedrugresistanceofleukemiastemcellsbyregulatingsurvivinexpressionthroughtheerkmskmapksignalingpathway AT xudandan sp1andcmycmodulatedrugresistanceofleukemiastemcellsbyregulatingsurvivinexpressionthroughtheerkmskmapksignalingpathway AT liuyuting sp1andcmycmodulatedrugresistanceofleukemiastemcellsbyregulatingsurvivinexpressionthroughtheerkmskmapksignalingpathway AT wangxiaoyan sp1andcmycmodulatedrugresistanceofleukemiastemcellsbyregulatingsurvivinexpressionthroughtheerkmskmapksignalingpathway AT wangxiao sp1andcmycmodulatedrugresistanceofleukemiastemcellsbyregulatingsurvivinexpressionthroughtheerkmskmapksignalingpathway AT yanhaizhao sp1andcmycmodulatedrugresistanceofleukemiastemcellsbyregulatingsurvivinexpressionthroughtheerkmskmapksignalingpathway AT zhangli sp1andcmycmodulatedrugresistanceofleukemiastemcellsbyregulatingsurvivinexpressionthroughtheerkmskmapksignalingpathway AT liuqiuying sp1andcmycmodulatedrugresistanceofleukemiastemcellsbyregulatingsurvivinexpressionthroughtheerkmskmapksignalingpathway AT chenwanqun sp1andcmycmodulatedrugresistanceofleukemiastemcellsbyregulatingsurvivinexpressionthroughtheerkmskmapksignalingpathway AT wangyifei sp1andcmycmodulatedrugresistanceofleukemiastemcellsbyregulatingsurvivinexpressionthroughtheerkmskmapksignalingpathway |